Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Smith

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Pageof 5